Brand Name
Rethymic
Generic Name
Thymocyte-Depleted
View Brand Information FDA approval date: October 08, 2021
Form: Implant
What is Rethymic (Thymocyte-Depleted)?
RETHYMIC ® is indicated for immune reconstitution in pediatric patients with congenital athymia. RETHYMIC is indicated for immune reconstitution in pediatric patients with congenital athymia. Limitations of Use : RETHYMIC is not indicated for the treatment of patients with severe combined immunodeficiency . Limitations of Use RETHYMIC is not indicated for the treatment of patients with severe combined immunodeficiency .
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Congenital Athymia Patient Registry of RETHYMIC
Summary: This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitu...